Literature DB >> 18626484

Reversal of visceral adiposity in candy-diet fed female Wistar rats by the CB1 receptor antagonist rimonabant.

A W Herling1, S Kilp, H-P Juretschke, C Neumann-Haefelin, M Gerl, W Kramer.   

Abstract

OBJECTIVE: The severity of obesity is often more determined by the distribution of fat depots rather than by body weight itself. Therefore, the effect of rimonabant on fat distribution pattern was investigated in female candy-fed Wistar rats.
DESIGN: Female Wistar rats were fed a high fat, high carbohydrate (candy-) diet for 12 weeks. During the last 6 weeks rats were treated with rimonabant. Food intake and body weight development were investigated, as well as effects on total body fat, especially visceral fat and ectopic lipid accumulation in skeletal muscle and liver, determined by in vivo magnetic resonance imaging/magnetic resonance spectroscopy.
RESULTS: Candy-diet increased body weight, which was predominantly due to the increased total fat mass with predominance of visceral fat accumulation. Treatment with rimonabant fully reversed the weight gain and fat deposition in the visceral cavity and skeletal muscle, in contrast to pair feeding. In spite of an only transient reduction of food intake, body weight reduction, as well as normalized body fat, reduced visceral fat and intramyocellular lipids were maintained over the treatment period.
CONCLUSIONS: We conclude that additional factors other than reduced caloric intake must be responsible for the improvements in these lipid parameters. The complete cluster of results is consistent with increased lipid oxidation caused by rimonabant.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18626484     DOI: 10.1038/ijo.2008.105

Source DB:  PubMed          Journal:  Int J Obes (Lond)        ISSN: 0307-0565            Impact factor:   5.095


  8 in total

1.  2-arachidonoylglycerol signaling in forebrain regulates systemic energy metabolism.

Authors:  Kwang-Mook Jung; Jason R Clapper; Jin Fu; Giuseppe D'Agostino; Ana Guijarro; Dean Thongkham; Agnesa Avanesian; Giuseppe Astarita; Nicholas V DiPatrizio; Andrea Frontini; Saverio Cinti; Sabrina Diano; Daniele Piomelli
Journal:  Cell Metab       Date:  2012-03-07       Impact factor: 27.287

2.  Acute cannabinoid receptor type 1 (CB1R) modulation influences insulin sensitivity by an effect outside the central nervous system in mice.

Authors:  D Song; R H J Bandsma; C Xiao; L Xi; W Shao; T Jin; G F Lewis
Journal:  Diabetologia       Date:  2011-02-22       Impact factor: 10.122

Review 3.  Re-visiting the Endocannabinoid System and Its Therapeutic Potential in Obesity and Associated Diseases.

Authors:  Joyce M Richey; Orison Woolcott
Journal:  Curr Diab Rep       Date:  2017-09-14       Impact factor: 4.810

4.  Effect of the cannabinoid receptor-1 antagonist rimonabant on inflammation in mice with diet-induced obesity.

Authors:  Qun Wang; Xiaoyuan D Perrard; Jerry L Perrard; Amir Mansoori; C Wayne Smith; Christie M Ballantyne; Huaizhu Wu
Journal:  Obesity (Silver Spring)       Date:  2010-09-30       Impact factor: 5.002

5.  Rimonabant prevents additional accumulation of visceral and subcutaneous fat during high-fat feeding in dogs.

Authors:  Joyce M Richey; Orison O Woolcott; Darko Stefanovski; L Nicole Harrison; Dan Zheng; Maya Lottati; Isabel R Hsu; Stella P Kim; Morvarid Kabir; Karyn J Catalano; Jenny D Chiu; Viorica Ionut; Cathryn Kolka; Vahe Mooradian; Richard N Bergman
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-04-14       Impact factor: 4.310

6.  Adipocyte cannabinoid receptor CB1 regulates energy homeostasis and alternatively activated macrophages.

Authors:  Inigo Ruiz de Azua; Giacomo Mancini; Raj Kamal Srivastava; Alejandro Aparisi Rey; Pierre Cardinal; Laura Tedesco; Cristina Maria Zingaretti; Antonia Sassmann; Carmelo Quarta; Claudia Schwitter; Andrea Conrad; Nina Wettschureck; V Kiran Vemuri; Alexandros Makriyannis; Jens Hartwig; Maria Mendez-Lago; Laura Bindila; Krisztina Monory; Antonio Giordano; Saverio Cinti; Giovanni Marsicano; Stefan Offermanns; Enzo Nisoli; Uberto Pagotto; Daniela Cota; Beat Lutz
Journal:  J Clin Invest       Date:  2017-10-16       Impact factor: 14.808

Review 7.  Targeting the Endocannabinoid CB1 Receptor to Treat Body Weight Disorders: A Preclinical and Clinical Review of the Therapeutic Potential of Past and Present CB1 Drugs.

Authors:  Thomas Murphy; Bernard Le Foll
Journal:  Biomolecules       Date:  2020-06-04

8.  Effect of different intensities of physical activity on cardiometabolic markers and vascular and cardiac function in adult rats fed with a high-fat high-carbohydrate diet.

Authors:  Romeo B Batacan; Mitch J Duncan; Vincent J Dalbo; Geraldine L Buitrago; Andrew S Fenning
Journal:  J Sport Health Sci       Date:  2016-08-03       Impact factor: 7.179

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.